Key facts
- Notable investors include Oost NL, Radboud University.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Philikos
- ·The full record, as it builds
Funding rounds
No funding rounds for Philikos are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Philikos
Developer of antibody-based therapies designed to treat severe immune disorders. The company platform offers a compound, T-Guard, which rebalances the immune system by depleting activated T cells and NK cells, enabling patients with conditions like scleroderma to achieve restored immune function and improved long-term health outcomes.
- Sector
- Healthcare
- HQ
- Nijmegen, Netherlands
- Founded
- 2023
- Employees
- 1
- Website
- philikos.com/
- Ownership
- Privately Held (backing)
Philikos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Philikos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Philikos in its N-PORT filings yet. We sweep new filings monthly.